NASDAQ:EVOK Evoke Pharma (EVOK) Stock Price, News & Analysis $2.76 +0.26 (+10.40%) Closing price 06/24/2025 03:59 PM EasternExtended Trading$2.76 +0.01 (+0.18%) As of 06/24/2025 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Evoke Pharma Stock (NASDAQ:EVOK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evoke Pharma alerts:Sign Up Key Stats Today's Range$2.54▼$2.8450-Day Range$2.15▼$3.8252-Week Range$1.94▼$12.32Volume23,096 shsAverage Volume124,513 shsMarket Capitalization$4.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Read More… Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address EVOK Stock News HeadlinesEvoke Pharma (NASDAQ:EVOK) Stock Price Crosses Below Two Hundred Day Moving Average - What's Next?June 18, 2025 | americanbankingnews.comBreakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK)June 14, 2025 | finance.yahoo.comWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.June 25, 2025 | Crypto Swap Profits (Ad)Evoke Pharma Inc.June 8, 2025 | wsj.comEvoke Pharma Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comEvoke Pharma Announces Presentation of New Research on Tardive Dyskinesia at Digestive Disease Week 2025April 30, 2025 | nasdaq.comEvoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025April 28, 2025 | globenewswire.comEvoke Pharma, Inc. (NASDAQ:EVOK) Just Reported And Analysts Have Been Cutting Their EstimatesMarch 16, 2025 | uk.finance.yahoo.comSee More Headlines EVOK Stock Analysis - Frequently Asked Questions How have EVOK shares performed this year? Evoke Pharma's stock was trading at $4.42 at the beginning of the year. Since then, EVOK shares have decreased by 37.6% and is now trading at $2.76. View the best growth stocks for 2025 here. How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) posted its quarterly earnings results on Monday, May, 12th. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.18. The specialty pharmaceutical company earned $3.08 million during the quarter, compared to analysts' expectations of $3.32 million. Evoke Pharma had a negative trailing twelve-month return on equity of 101.91% and a negative net margin of 43.80%. When did Evoke Pharma's stock split? Evoke Pharma's stock reverse split on Thursday, August 1st 2024.The 1-12 reverse split was announced on Thursday, August 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Evoke Pharma? Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings5/12/2025Today6/25/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EVOK CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.35 million Net Margins-43.80% Pretax Margin-43.80% Return on Equity-101.91% Return on Assets-33.75% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio1.50 Sales & Book Value Annual Sales$10.25 million Price / Sales0.40 Cash FlowN/A Price / Cash FlowN/A Book Value$4.74 per share Price / Book0.58Miscellaneous Outstanding Shares1,490,000Free Float1,402,000Market Cap$4.11 million OptionableNot Optionable Beta0.04 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:EVOK) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.